Efficacy and safety of valsartan compared with enalapril at different altitudes

Vista sencilla de ítem
dc.contributor.authorBotero, R.
dc.contributor.authorMatiz, H.
dc.contributor.authorMarı́a, E.
dc.contributor.authorOrejarena, H.
dc.contributor.authorBlanco, M.
dc.contributor.authorVelez, J.R.
dc.contributor.authorDel Portillo, H.
dc.date.accessioned2021-02-09T18:46:05Z
dc.date.available2021-02-09T18:46:05Z
dc.date.issued2000
dc.description.abstractenglishTo compare the safety, tolerability, and antihypertensive efficacy of valsartan with enalapril at different altitudes. A total of 142 adult Colombian outpatients with mild to moderate essential hypertension were recruited in 3 cities at different altitudes (Bogotá at 2600 m, Medellı́n at 1538 m and Barranquilla at 100 m) and randomized in an open label fashion to receive either valsartan 80 mg once daily or enalapril 20 mg once daily for 8 weeks. Those patients not responding at 4 weeks received additional 1.25 mg indapamide daily during the remaining trial period. The primary efficacy variable was the change in mean sitting diastolic blood pressure (SDBP) from baseline to 4 weeks. Secondary efficacy variables included the change in mean sitting systolic blood pressure (SSBP). The primary criterion for tolerability was the incidence of adverse experiences. Both valsartan and enalapril reduced mean SDBP and SSBP with similar efficacy, independent of altitude. Adverse events irrespective of relationship to trial drug were reported by 12 patients (18.8%) on valsartan and by 15 (23.4%) patients on enalapril. Enalapril was associated with a significantly (P<0.05) higher rate of dry cough and more cases of headache than valsartan. Valsartan 80 mg once daily is as effective as enalapril 20 mg once daily in reducing blood pressure, with tolerability profile at least as good as enalapril’s.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/S0167-5273(99)00194-1
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1874-1754
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5284
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalInternational Journal of Cardiologyspa
dc.relation.ispartofseriesInternational Journal of Cardiology, 1874-1754, Vol. 72, No. 3, 2000, p. 247-254spa
dc.relation.urihttps://www.internationaljournalofcardiology.com/article/S0167-5273(99)00194-1/fulltext
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2000
dc.rights.localAcceso abiertospa
dc.subject.keywordsValsartanspa
dc.subject.keywordsEnalaprilspa
dc.subject.keywordsAngiotensin II receptor blockerspa
dc.subject.keywordsAT1 antagonistspa
dc.subject.keywordsIndapamidespa
dc.subject.keywordsEssential hypertensionspa
dc.titleEfficacy and safety of valsartan compared with enalapril at different altitudesspa
dc.title.translatedEfficacy and safety of valsartan compared with enalapril at different altitudesspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos